Research ArticleNEUROPHARMACOLOGY
Pharmacological Properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: II. Neurophysiological Characterization and Broad Preclinical Efficacy in Cognition and Schizophrenia of a Potent and Selective Histamine H3 Receptor Antagonist
Gerard B. Fox, Timothy A. Esbenshade, Jia Bao Pan, Richard J. Radek, Kathleen M. Krueger, Betty B. Yao, Kaitlin E. Browman, Michael J. Buckley, Michael E. Ballard, Victoria A. Komater, Holly Miner, Min Zhang, Ramin Faghih, Lynne E. Rueter, R. Scott Bitner, Karla U. Drescher, Jill Wetter, Kennan Marsh, Martine Lemaire, Roger D. Porsolt, Youssef L. Bennani, James P. Sullivan, Marlon D. Cowart, Michael W. Decker and Arthur A. Hancock
Journal of Pharmacology and Experimental Therapeutics April 2005, 313 (1) 176-190; DOI: https://doi.org/10.1124/jpet.104.078402
Gerard B. Fox
Timothy A. Esbenshade
Jia Bao Pan
Richard J. Radek
Kathleen M. Krueger
Betty B. Yao
Kaitlin E. Browman
Michael J. Buckley
Michael E. Ballard
Victoria A. Komater
Holly Miner
Min Zhang
Ramin Faghih
Lynne E. Rueter
R. Scott Bitner
Karla U. Drescher
Jill Wetter
Kennan Marsh
Martine Lemaire
Roger D. Porsolt
Youssef L. Bennani
James P. Sullivan
Marlon D. Cowart
Michael W. Decker
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|
Log in using your username and password
Purchase access
You may purchase access to this article. This will require you to create an account if you don't already have one.
In this issue
Research ArticleNEUROPHARMACOLOGY
Pharmacological Properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: II. Neurophysiological Characterization and Broad Preclinical Efficacy in Cognition and Schizophrenia of a Potent and Selective Histamine H3 Receptor Antagonist
Gerard B. Fox, Timothy A. Esbenshade, Jia Bao Pan, Richard J. Radek, Kathleen M. Krueger, Betty B. Yao, Kaitlin E. Browman, Michael J. Buckley, Michael E. Ballard, Victoria A. Komater, Holly Miner, Min Zhang, Ramin Faghih, Lynne E. Rueter, R. Scott Bitner, Karla U. Drescher, Jill Wetter, Kennan Marsh, Martine Lemaire, Roger D. Porsolt, Youssef L. Bennani, James P. Sullivan, Marlon D. Cowart, Michael W. Decker and Arthur A. Hancock
Journal of Pharmacology and Experimental Therapeutics April 1, 2005, 313 (1) 176-190; DOI: https://doi.org/10.1124/jpet.104.078402
Research ArticleNEUROPHARMACOLOGY
Pharmacological Properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: II. Neurophysiological Characterization and Broad Preclinical Efficacy in Cognition and Schizophrenia of a Potent and Selective Histamine H3 Receptor Antagonist
Gerard B. Fox, Timothy A. Esbenshade, Jia Bao Pan, Richard J. Radek, Kathleen M. Krueger, Betty B. Yao, Kaitlin E. Browman, Michael J. Buckley, Michael E. Ballard, Victoria A. Komater, Holly Miner, Min Zhang, Ramin Faghih, Lynne E. Rueter, R. Scott Bitner, Karla U. Drescher, Jill Wetter, Kennan Marsh, Martine Lemaire, Roger D. Porsolt, Youssef L. Bennani, James P. Sullivan, Marlon D. Cowart, Michael W. Decker and Arthur A. Hancock
Journal of Pharmacology and Experimental Therapeutics April 1, 2005, 313 (1) 176-190; DOI: https://doi.org/10.1124/jpet.104.078402
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement